Belimed AG, headquartered in Switzerland (CH), is a leading provider in the healthcare and life sciences industry, specialising in sterilisation and infection control solutions. Founded in 1947, the company has established a strong presence in Europe, North America, and Asia, delivering innovative products and services that enhance patient safety and operational efficiency. Belimed's core offerings include advanced sterilisation equipment, automated cleaning systems, and comprehensive service solutions, all designed to meet the stringent demands of modern healthcare environments. Their commitment to quality and innovation has positioned them as a trusted partner for hospitals and laboratories worldwide. With a focus on sustainability and cutting-edge technology, Belimed AG continues to achieve notable milestones, reinforcing its status as a market leader in infection prevention and control.
How does Belimed AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Belimed AG's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Belimed AG, headquartered in Switzerland (CH), currently does not report specific carbon emissions data, as no figures are available for the most recent year. The company is a current subsidiary of Metall Zug AG, which may influence its climate commitments and emissions reporting. While Belimed AG has not set specific reduction targets or initiatives, it is important to note that it inherits its climate performance metrics from its parent company, Metall Zug AG. This relationship may provide a framework for future climate action and emissions reduction strategies. As part of the broader industry context, companies like Belimed AG are increasingly expected to engage in climate initiatives and set science-based targets to mitigate their environmental impact. However, without specific data or commitments from Belimed AG, it is challenging to assess their current standing in terms of carbon emissions and climate action.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 1,947,000 | 0,000,000 | 
| Scope 2 | 1,359,000 | 000,000 | 
| Scope 3 | 722,000 | 000,000 | 
Belimed AG's Scope 3 emissions, which increased by 22% last year and increased by approximately 22% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 29% of total emissions under the GHG Protocol, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Belimed AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.